-- Finished the first quarter of 2009 as the #1 out of 514 funds as
judged by year-to-date performance by Morningstar within the category of
midcap blend.
-- Ranked #2 out of 380 midcap-core funds based on investment returns by
the Wall Street Journal for the one year period ending 9/30/09; the Fund's
first full year following July 1, 2008 inception.
-- Achieved Lipper's #1 ranking out of 359 midcap core funds for the one
year period ending 6/30/09.
"In its first full calendar year, we believe our fund performed
exceptionally well in volatile and uncertain market conditions," explained
Robin John, co-founder of the Gilead Fund. "Our strategy of combining
quantitative analytics with intensive research and qualitative assessments
is designed to capitalize on opportunities in both bull and bear markets.
"We capitalized on opportunities to add to our portfolio equities we
believe offer significant long-term appreciation, and to make these
purchases at excellent values," noted John. "While about two-thirds of our
portfolio consists of long-term 'commitment' holds, our strategy and
analytical capabilities enable us to dedicate a third of our portfolio to
tactical equity buys and sells that exploit short-term market
inefficiencies resulting from overbuying and overselling."
The Eventide Gilead Fund uses an investment process developed by portfolio
manager Finny Kuruvilla MD, PhD that uses multi-dimensional analytics with
a goal of high returns relative to the market and low volatility. Hallmarks
of the fund's investment process include dynamic fundamental analysis,
proprietary technical models, Capital Asset Pricing Model risk management,
values-based screens and the 'Masters Select' strategy which utilizes a
collective intelligence of today's top performing fund managers and
research analysts. This portfolio management process produced market
outperformance through both the bear and bull markets of 2009.
Dr. Kuruvilla said: "We were particularly satisfied that the Eventide
Gilead Fund out-performed our benchmark indices while investing in
companies that operate with integrity and profit from ethical and
sustainable activities. We believe there is a strong correlation between
companies that operate in sustainable, responsible way and are able to
generate long-term shareholder value. This includes managing businesses
practices that benefit the environment and society, and sound management
and corporate governance that supports the well-being and productivity of
employees."
Examples of the Fund's holdings that illustrate this investment approach
include Kinder-Morgan Management LLC and Momenta Pharmaceuticals, Inc.
Kinder-Morgan operates more than 14,000 miles of natural gas pipelines
serving North America. Dr. Kuruvilla noted natural gas is a clean,
plentiful fuel with significant growth prospects, and he said the company
is managed to generate shareholder value and has historically returned a 9%
stock dividend to shareholders.
With the ability to analyze and replicate even complex prescription
medications, Momenta is able to develop generic alternatives that can be
made available at competitive prices. "We feel the company has a superb
business model, a sound track record, and also promotes pricing competition
that can make lower-cost medications available," Dr. Kuruvilla explained.
Looking ahead to 2010, Dr. Kuruvilla said he believes the markets will be
relatively stable, consistent with modest economic improvement, but that
the current market is overbought. "I believe it will be possible to
out-perform benchmark indices by making very selective purchases and
capitalizing on market inefficiencies. We feel our statistically based
investing model is designed to perform well in a variety of market
conditions." He noted the healthcare sector continues to offer significant
buying opportunities because of legitimate but exaggerated investor
concerns about regulation and industry changes.
The Eventide Gilead Fund is managed by Eventide Asset Management, a
Boston-based investment advisory firm that is committed to investing in
values-based companies and was launched July 1, 2008. According to
Managing Partner of Eventide Asset Management, Robin John, "It could truly
impact business culture if more and more conscientious investors directed
their capital into products and businesses that supported their values."
The S&P 500 is an index created by Standard & Poor's and is considered to
represent the performance of the stock market generally. It is not an
investment product available for purchase. Kinder-Morgan comprised 1.73% of
the Fund's net assets and Momenta Pharmaceuticals comprised 2.56% of net
assets portfolio as of December 31, 2009. Portfolio holdings subject to
change.
Performance is historic and does not guarantee future results. Investment
return and principal value will fluctuate with changing market conditions
so that when redeemed, shares may be worth more or less than their original
cost. Current performance may be lower or higher than the performance data
quoted. To obtain the most recent month end performance information or the
fund's prospectus please call the fund, toll free at 1.877.453.7877. You
can also obtain a prospectus at www.eventidefunds.com.
An investor should consider the Fund's investment objectives, risks,
charges and expenses carefully before investing or sending money. This and
other important information about the Eventide Gilead Fund can be found in
the Fund's prospectus. Please read the prospectus carefully before
investing. The Fund is distributed by Matrix Capital Group, Inc., New York,
NY 10017.
Contact Information: Contacts: The Eventide Gilead Fund Robin John 617-878-2135 Media: Cindy Martin Capital Insight Partners 847-864-9540